MARA Holdings moved 1,000 BTC worth about $82.8 million to Binance and Gate over five days, representing 2.8% of its reported Bitcoin reserves. While this raised questions about possible sales, deposits to exchanges don't confirm actual selling. MARA previously sold large Bitcoin amounts to fund its AI expansion and reduce debt. Bitcoin faces resistance at $82,500, with analysts watching for price moves that could influence market trends. Traders should monitor if MARA confirms sales and whether Bitcoin sustains gains above key resistance levels.
MARA Holdings' recent Bitcoin movements provide context for cryptocurrency trends. For readers following crypto markets, here is Pluang's snapshot as of Oct 19, 2026 15:02 WIB: 41 of 50 major cryptocurrencies rose today. DOT rose 2.62% to Rp20.273 with 89% buy orders, BAT increased 2.53% to Rp3.300 with 93% buy orders, and SOL gained 2.51% to Rp1.898.186 with a near-even buy/sell split.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
